# Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia

> **NCT02035215** · PHASE3 · UNKNOWN · sponsor: **Kuhnil Pharmaceutical Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Hyperlipidemia, Familial Combined

## Interventions

- **DRUG:** Atorvastatin 20mg
- **DRUG:** Omega-3-acids ethylesters 90 4g
- **OTHER:** Placebo(Omega-3-acids ethylesters 90)

## Key facts

- **NCT ID:** NCT02035215
- **Lead sponsor:** Kuhnil Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2014-10
- **Final completion:** 2014-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2014-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02035215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02035215, "Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02035215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*